Agilent Technologies, Inc. (NYSE: A)
Company Overview
Agilent Technologies reported Q3 fiscal 2026 results on Wednesday — the same night Nvidia posted its historic $96.2 billion quarter — and in the shadow of that event, one of the cleanest earnings beats in the life sciences sector went almost entirely unnoticed. Adjusted EPS of $1.62 beat the $1.49 consensus by $0.13, an 8.7% positive surprise, on revenue of $1.88 billion that exceeded the $1.84 billion estimate and grew 8.1% year-over-year. Full-year guidance was raised to $7.49–$7.51 billion in revenue with adjusted EPS of $6.18–$6.21 — both above prior analyst consensus — marking the second consecutive quarter of guidance increases.
Agilent makes the analytical instruments that global pharmaceutical, biotech, food safety, environmental testing, and diagnostics laboratories depend on — liquid chromatography systems, mass spectrometers, gene expression arrays, flow cytometers. These are the tools that measure drug purity, sequence genetic samples, test food for contamination, and increasingly, analyze the GLP-1 obesity drug compounds that have become the single most important growth driver in global pharmaceutical manufacturing.
When we wrote Agilent on June 1 following its Q2 17% single-session surge, the story was a cyclical recovery from a pharma spending pause. Three months later, the story is something more durable: GLP-1 momentum delivering more than 70% year-over-year growth, an OpenAI partnership mobilized for the commercial customer journey, five of the top 10 global pharma companies placing reshoring orders in Q3 alone, and a China recovery growing 9% against flat expectations. This is not the same company the market was discounting a year ago.
Key Technical and Fundamental Drivers
8.7% EPS Beat + 140 Basis Point Revenue Upside → Second Consecutive Guidance Raise
Adjusted EPS of $1.62 beat the $1.49 consensus by 8.7%, while revenue of $1.88 billion exceeded guidance by 140 basis points at the high end — the same magnitude of outperformance that drove the June 1 17% surge. Full-year EPS guidance was raised to $6.18–$6.21 at a midpoint of $6.195, above the prior $6.06 consensus, and revenue guidance raised to $7.49–$7.51 billion. CEO Padraig McDonnell said: “We delivered an excellent third quarter with strong performance in both the top and bottom lines. Our results clearly demonstrate the sustained momentum unlocked by our exceptional commercial and operational execution.”
GLP-1 Momentum → 70% Year-Over-Year Growth, CDMO Business Up 30%
Pharma revenue grew 12% in Q3, with GLP-1 momentum delivering more than 70% year-over-year growth and the Advanced Therapeutics CDMO business growing nearly 30%, with a robust order book for future capacity. The GLP-1 obesity drug boom — driven by Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound — requires extensive analytical instrumentation at every stage of production: raw material testing, in-process analysis, final product release testing, and stability monitoring. Agilent’s LC-MS systems and chromatography instruments are embedded in the manufacturing workflows of the largest GLP-1 producers globally. The 70% growth in this specific category is not a coincidence — it is the direct financial read-through of the most consequential pharmaceutical product cycle in a decade.
OpenAI Partnership → Enterprise AI Strategy “Moved Into Execution”
Starting last quarter, Agilent moved its enterprise AI strategy into execution, mobilizing a partnership with OpenAI and BCGX Advanced Solutions focused on the commercial customer journey, and continuing to build the Agilent AI Center of Excellence. CEO McDonnell said: “Combining AI with Agilent’s proprietary data, scientific knowledge, and customer understanding enables us to redesign workflows, improving how decisions are made and how work gets done.” The OpenAI partnership is not a press release — it is active deployment in commercial operations, with new online orders growing in the low teens in Q3 as a direct result of the digital and AI initiatives already in production. For a life sciences instrumentation company, applying AI to proprietary scientific data and customer workflows creates a competitive advantage that generic AI tools cannot replicate.
China Recovery → 9% Growth vs. Flat Expectations
China showed a notable recovery, growing 9% in Q3 versus flat expectations, driven by strong execution in pharma and food, with momentum expected to continue into year-end. China has been the most consistent headwind in Agilent’s results for the past two years — government funding delays, instrument procurement slowdowns, and reduced academic research spending all compressed revenue from the region. A 9% actual print against flat expectations represents the most significant positive China surprise in Agilent’s recent history, and management’s confidence that momentum will continue into year-end shifts China from a headwind to a potential tailwind for Q4.
Five of Top 10 Global Pharma Companies Placed Reshoring Orders in Q3
Out of the first operation onshore or reshoring orders Agilent completed, five of the top 10 global pharma companies placed orders in Q3 alone, with revenue expected to start coming in during FY2027. The U.S. pharmaceutical reshoring initiative — driven by supply chain concerns from the pandemic, executive orders on critical drug supply, and the BIOSECURE Act limiting Chinese contract manufacturers — is creating a wave of new domestic laboratory and manufacturing capacity that requires Agilent instrumentation. Five top-10 pharma companies ordering in a single quarter is the earliest concrete financial evidence that this multi-year reshoring cycle is beginning to show up in Agilent’s order book.
210 Basis Points of Operating Margin Expansion → Ignite Operating System Delivering
Operating margin of 27.2% excluding tariff refunds expanded 210 basis points year-over-year, with free cash flow reaching $439 million after $80 million in capital spending. The Ignite Operating System — Agilent’s internal efficiency program — drove more than 100 basis points of full-year margin expansion with further improvement expected. A company simultaneously accelerating revenue growth and expanding operating margins by 210 basis points is demonstrating the kind of operating leverage that turns a recovery story into a compounding one.
Market Takeaway
Agilent’s Q3 print last Wednesday — lost in the noise of Nvidia’s historic quarter and the Jackson Hole Fed symposium — is the kind of result that tends to generate the most durable post-earnings moves precisely because it wasn’t the story anyone was watching. Operating margin of 27.2% ex-tariff refunds expanded 210 basis points year-over-year, free cash flow reached $439 million, and the guidance raise was grounded in three simultaneous tailwinds — GLP-1 instrument demand at 70% growth, China recovery at 9%, and reshoring orders from five top-10 pharma companies — rather than any single driver that could prove temporary.
The honest risks deserve direct treatment. The EPS beat included a $0.06 benefit from tariff refunds — a temporary tailwind that the ex-refund EPS of $1.56 (still an 8-cent beat against a $1.48 clean consensus) confirms is additive rather than foundational. Applied Markets and Chemicals grew 7%, solid but below the pharma pace — the business is still unevenly recovering with pharma leading and academic/government markets lagging. And the reshoring revenue CEO McDonnell described as “not linear” — arriving unevenly by quarter in FY2027 — means the order book visibility is real but the revenue timing will create quarter-to-quarter noise that can frustrate investors expecting smooth linearity. Average analyst price target of $158.21 implies 13.7% upside from current levels — meaningful, but more modest than the implied upside in some of the larger-discount names the series has covered this summer. For traders watching Monday’s open as the market digests Nvidia’s blockbuster print, Chairman Warsh’s Jackson Hole remarks, and Canada’s retaliatory tariff announcement all at once, Agilent offers the story that the week’s biggest events made easy to overlook: a life sciences instrumentation company with an OpenAI partnership, 70% GLP-1 momentum, a Chinese recovery that surprised even management, and five top-10 pharma companies already placing the reshoring orders that will define FY2027 revenue — all confirmed in an earnings call that happened while the world was watching Jensen Huang.